SCHEMBL6489902

SCHEMBL6489902

Cc1cc(O)c(C#N)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 2/20 0.41
ESR1 P03372 7/20 0.41
ESR2 Q92731 7/20 0.41
TSHR P16473 1/20 0.35
KHK P50053 1/20 0.35
EGFR P00533 1/20 0.34
ERBB2 P04626 1/20 0.34
AR P10275 1/20 0.34
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
MAPT P10636 1/20 0.33
G6PD P11413 1/20 0.33
CYP2C9 P11712 1/20 0.33
PKM P14618 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23451204 0.92 ESR1 (0.41) TRPV4ESR1ESR2TSHREGFR
SCHEMBL1128865 0.82 TRPV4 (0.46) TRPV4ESR1ESR2KHKAR
SCHEMBL27819091 0.82 TSHR (0.41) ESR1ESR2TSHREGFRERBB2
SCHEMBL23730334 0.82 TRPV4 (0.46) TRPV4ESR1ESR2TSHRKHK
SCHEMBL14932734 0.80 TRPV4 (0.45) TRPV4ESR1ESR2TSHRKHK
SCHEMBL13003845 0.80 TRPV4 (0.56) TRPV4TSHRKHKCYP11B1CYP11B2
SCHEMBL862662 0.76 TRPV4 (0.50) TRPV4TSHRKHKCYP11B1CYP11B2
SCHEMBL30583466 0.76 TRPV4 (0.50) TRPV4TSHRKHKCYP11B1CYP11B2
SCHEMBL10257221 0.76 TRPV4 (0.40) TRPV4ESR1ESR2TSHRKHK
SCHEMBL6722032 0.75 KHK (0.43) TRPV4ESR1ESR2KHKCYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1235870-C Novel use of phenyl hetero alkylamine derivatives ASTRAZENECA AB (SE) 2006-01-11 CN disclosed
US-6887871-B2 Use of phenylheteroakylamine derivatives ASTRAZENECA AB (SE) 2005-05-03 US disclosed
EP-1263711-B1 NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES ASTRAZENECA AB (SE) 2004-12-15 EP disclosed
US-20030158185-A1 Novel use of phenylheteroakylamine derivatives ASTRAZENECA AB (SE) 2003-08-21 US disclosed
CN-1411435-A Novel use of phenylheteroalkylamine derivatives ASTRAZENECA AB (SE) 2003-04-16 CN disclosed
EP-1263711-A1 NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES AstraZeneca AB (SE) 2002-12-11 EP disclosed
WO-2001062704-A1 NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES ASTRAZENECA AB (SE) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158185-A1 Novel use of phenylheteroakylamine derivatives NOS1, XDH, NOS2 TRPV4 4055/4885ESR1 3717/4885ESR2 1212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.